Article Text

Download PDFPDF

54 Diagnostic accuracy of serum insulin-like growth factor binding protein 2 for ovarian cancer
  1. Pande Kadek Aditya Prayudi,
  2. I Nyoman Gede Budiana and
  3. Ketut Suwiyoga
  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Faculty of Medicine Udayana University/Sanglah General Hospital


Introduction/Background Insulin-like growth factor binding protein-2 (IGFBP2) have been shown to play important roles in the pathogenesis of ovarian cancer. It also serves as a potential biomarker for prognosis of ovarian cancer. However, its role in the diagnosis of ovarian cancer has never been studied. This study is aimed to determine the diagnostic accuracy of serum IGFBP2 in differentiating between malignant and benign ovarian lesion.

Methodology Preoperative IGFBP2 level was determined from the serum of 76 patients with adnexal mass who underwent exploratory laparotomy and subsequent histopathology examination at Sanglah General Hospital, Denpasar, Bali, Indonesia. Diagnostic accuracy of IGFPB2 level was determined from the receiver operating characteristics curve (ROC).

Results Of the 76 patients, 46 patients were diagnosed with ovarian cancer and 30 patients were diagnosed with benign ovarian lesions. Serum IGFBP2 level was significantly higher in patients with ovarian cancer, as compared to those with benign ovarian lesions (median: 945.9 vs. 401.5 g/ml, p<0.001). Using a cut off value of 551.6 ng/ml, the area under the ROC (AUC) for diagnosing ovarian cancer was 0.815 (95% CI 0.721–0.910, p<0.001), sensitivity was 76.1%, specificity was 80%, and diagnostic odd ratio (DOR) was 12.7 (95% CI 4.1–39.0, p<0.001). The diagnostic performance of IGFBP2 was enhanced in postmenopausal women [AUC 0.893 (95% CI 0.771–1.000, p=0.002), sensitivity 85%, specificity 85.7%, DOR 34 (95% CI 2.9–392.8), p=0.001] and in advance stage [AUC 0.904 (95% CI 0.806–1.000, p<0.001), sensitivity 87.5%, specificity 80%, DOR 28 (95% CI 6.2–126), p<0.001].

Conclusion IGFBP2 is a potential biomarker for diagnosis of ovarian cancer.

Disclosures Pande Kadek Aditya Prayudi discloses no potential conflict of interest. I Nyoman Gede Budiana discloses no potential conflict of interest. Ketut Suwiyoga discloses no potential conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.